Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead. (PubMed, J Inflamm Res) - Oct 7, 2026 - "Risankizumab, mirikizumab, and guselkumab - three monoclonal antibodies targeting the p19 subunit of IL-23 - have each completed Phase 3 clinical development programs in both Crohn's disease (CD) and ulcerative colitis (UC), demonstrating consistent efficacy across a broad spectrum of disease severity...Real-world data, predominantly available for risankizumab in CD and mirikizumab in UC, confirm meaningful clinical and endoscopic responses in refractory populations, including patients with prior ustekinumab exposure...Key evidence gaps persist, including the absence of head-to-head data in UC, limited long-term outcomes beyond 52 weeks, and the lack of validated predictive biomarkers for patient stratification. This narrative review synthesizes the biological rationale, clinical trial evidence, real-world data, and safety profiles, focusing on clinical positioning of IL-23p19 inhibitors in IBD in the context of precision medicine."
Journal • Review • Cardiovascular • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL12A • IL23A
|
|
Alessandro Armuzzi; Arianna Dal Buono; Cristina Bezzio; Erica Bartolotta; Giulia Migliorisi; Giuseppe Privitera; Laura Loy; Roberto Gabbiadini
|